Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hartmut Grasemann

Showing results (1-10 of 138) with videos related to

Pageof 14
Sort By:
Molecular and Cellular Pediatrics|November 7, 2015
Metabolic origins of childhood asthmaHartmut Grasemann
Current Pharmaceutical Design|January 11, 2012
New developments in pharmaceutical treatments for cystic fibrosisHartmut Grasemann
Pediatric Pulmonology|July 16, 2010
Do the cysteine proteinases cathepsin B and S contribute to cystic fibrosis lung disease?Hartmut Grasemann
The New England Journal of Medicine|November 4, 2017
CFTR Modulator Therapy for Cystic FibrosisHartmut Grasemann
Annals of the American Thoracic Society|January 21, 2025
Is There a Role for Lumacaftor/Ivacaftor in Young Children with Cystic Fibrosis?Isaac Martin, Hartmut Grasemann
Paediatric Respiratory Reviews|July 15, 2020
Oxidative stress and obesity-related asthmaHartmut Grasemann, Fernando Holguin
British Journal of Haematology|June 17, 2004
Gender-specific disease modification by NOS3Hartmut Grasemann, Felix Ratjen
Pediatric Pulmonology|April 6, 2021
An association of the arginase 1 gene with preschool wheezing phenotypesHartmut Grasemann, Fernando Holguin
The New England Journal of Medicine|November 1, 2023
Cystic FibrosisHartmut Grasemann, Felix Ratjen
Expert Opinion on Emerging Drugs|September 4, 2010
Emerging therapies for cystic fibrosis lung diseaseHartmut Grasemann, Felix Ratjen
Pageof 14

Showing results (1-10 of 138) with videos related to

Sort By:
Pageof 14
Molecular and Cellular Pediatrics|November 7, 2015
Metabolic origins of childhood asthmaHartmut Grasemann
Current Pharmaceutical Design|January 11, 2012
New developments in pharmaceutical treatments for cystic fibrosisHartmut Grasemann
Pediatric Pulmonology|July 16, 2010
Do the cysteine proteinases cathepsin B and S contribute to cystic fibrosis lung disease?Hartmut Grasemann
The New England Journal of Medicine|November 4, 2017
CFTR Modulator Therapy for Cystic FibrosisHartmut Grasemann
Annals of the American Thoracic Society|January 21, 2025
Is There a Role for Lumacaftor/Ivacaftor in Young Children with Cystic Fibrosis?Isaac Martin, Hartmut Grasemann
Paediatric Respiratory Reviews|July 15, 2020
Oxidative stress and obesity-related asthmaHartmut Grasemann, Fernando Holguin
British Journal of Haematology|June 17, 2004
Gender-specific disease modification by NOS3Hartmut Grasemann, Felix Ratjen
Pediatric Pulmonology|April 6, 2021
An association of the arginase 1 gene with preschool wheezing phenotypesHartmut Grasemann, Fernando Holguin
The New England Journal of Medicine|November 1, 2023
Cystic FibrosisHartmut Grasemann, Felix Ratjen
Expert Opinion on Emerging Drugs|September 4, 2010
Emerging therapies for cystic fibrosis lung diseaseHartmut Grasemann, Felix Ratjen
Pageof 14